Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tobin Schilke Insider Profile
4 Followers
Tobin Schilke, CFO at Achaogen, holds 192.67K shares in Revance Therapeutics (Ticker: RVNC), holds 47.75K shares in Achaogen (Ticker: AKAOQ). Most recently, Tobin Schilke Sold ― shares of Revance Therapeutics on Mar 19, 2024 for an estimated value of 67.44K.
Profitable Transactions
4 out of 4 Profitable Transactions
Average Return
+55.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
CFO
Roles that Tobin Schilke holds in companies
Most Profitable Insider Trade
The most profitable trade made by Tobin Schilke
Tobin Schilke's Trading History
Achaogen
Jun 28, 2018
―
Uninformative Buy
―
$1.19K
Revance Therapeutics
Mar 19, 2024
CFO
Informative Sell
67.44K
$655.06K
List of latest transactions for each holding click on a transaction to see Tobin Schilke's performance on stock
You May Also Like
Tobin Schilke insider profile FAQ
What is the percentage of profitable transactions made by Tobin Schilke?
The percentage of profitable transactions made by Tobin Schilke is 100%.
What is the average return per transaction made by Tobin Schilke?
The average return per transaction made by Tobin Schilke is 55.60%.
What stocks does Tobin Schilke hold?
Tobin Schilke holds: AKAOQ, RVNC stocks.
What was Tobin Schilke’s latest transaction?
Tobin Schilke latest transaction was an Informative Sell of $67.44K.
What was Tobin Schilke's most profitable transaction?
Tobin Schilke’s most profitable transaction was an Informative Sell of RVNC stock on May 16, 2023. The return on the trade was 89.80%.
What is Tobin Schilke's role in Achaogen?
Tobin Schilke's role in Achaogen is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.